Modifying prescribing behaviour of angiotensin receptor blockers by selectively rescinding managerial prior authorization requirements for losartan

British Journal of Clinical Pharmacology

Volumn 72, Issue 6, 2011, Pages 997-1001

  Kahan, Natan R ^b,d   Chinitz, David P ^b   Blackman, Shimon ^a   Waitman, Dan Andrei ^a   Vardy, Daniel A ^a,c  

^a Leumit Health Care Services   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Angiotensin receptor blocker; Drug utilization analysis; Managed care; Managerial experiment; Prior authorization

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; VALSARTAN;

ARTICLE; DRUG COST; ELECTRONIC PRESCRIBING; HEALTH CARE POLICY; HEALTH MAINTENANCE ORGANIZATION; HEART FAILURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROTEINURIA;

EID: 80855138601     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04044.x     Document Type: Article

References (6)

1. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm 2001; 4: 297-302.
2. LaPensee KT. Analysis of a prescription drug prior authorization program in a Medicaid health maintenance organization. J Manag Care Pharm 2003; 9: 36-44.
3. Koike A, Klap R, Unützer J. Utilization management in a large managed behavioral health organization. Psychiatr Serv 2000; 51: 621-6.
4. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004; 23: 135-46.
5. Heran BS, Wong MMY, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008; (4): CD003822. DOI:10.1002/14651858.CD003822.pub2.
6. Fischer MA, Choudhry NK, Winkelmeyer WC. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff 2007; 26: 800-7.